Frontiers in Diabetes / The Insulinotropic Gut Hormone Glucagon-Like Peptide-1

Frontiers in Diabetes; Bd 13

---

Glucagon-like peptide-1 (GLP-1) is a promising new therapeutic tool for the treatment of diabetes. Since the first reports describing its potent insulinotropic activity were published about a decade ago, knowledge of the incretin hormones, and GLP-1 in particular, has increased significantly. This timely volume summarizes what is now known about the molecular biology, physiology and pharmacology of GLP-1. Thorough coverage is given to the physiology of the hormone, including its generation, release and actions at pancreatic and extrapancreatic tissues. The intracellular mechanisms of GLP-1 are also described in detail. Discussion of the molecular biology includes the structure and functions of the genes coding for proglucagon and the GLP-1 receptor. A special feature of the book is the clinical information provided which includes data on the expression and release of GLP-1 and its potential use as a therapeutic agent for diabetes. Presenting the results of exciting new research, this book should be a valuable reference for endocrinologists, gastroenterologists, pharmacologists, physiologists and biochemists interested in this important hormone.